| ||
| Data on Vivus' Qnexa Published Zacks.com We note that Vivus is evaluating Qnexa as a potential treatment for weight loss, type II diabetes and obstructive sleep apnea. The candidate is in mid-stage development for type II diabetes and obstructive sleep apnea. We note that in October 2010, ... See all stories on this topic » |
Wednesday, April 13, 2011
Google Alert - weight loss
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment